Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
Standard
Experimental panic provocation in healthy man-a translational role in anti-panic drug development? / Kellner, Michael.
in: DIALOGUES CLIN NEURO, Jahrgang 13, Nr. 4, 4, 2011, S. 485-493.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
AU - Kellner, Michael
PY - 2011
Y1 - 2011
N2 - Experimental neurochemical provocation of panic attacks in susceptible human subjects has considerably expanded our knowledge of the pathophysiology and psychopharmacology of panic disorder. Some panicogens also elicit short-lived panic-like states in healthy man. This offers the opportunity to assess the anti-panic action of drugs in proof-of-concept studies. However, from current data it is still unclear whether experimental panic in healthy man is a valid translational model. Most such studies in healthy volunteers have been performed using a cholecystokinin tetrapeptide (CCK-4) challenge. While CCK-4 panic was blocked by alprazolam pretreatment, escitalopram showed negative results in healthy man. Preliminary findings on novel investigational drugs and a few problematic results will be reviewed. Small sample sizes in many panic provocation studies, lack of dose-response aspects, and still-insufficient knowledge about the biological underpinning of experimental and spontaneous panic limit the interpretation of existing findings and should inspire further research.
AB - Experimental neurochemical provocation of panic attacks in susceptible human subjects has considerably expanded our knowledge of the pathophysiology and psychopharmacology of panic disorder. Some panicogens also elicit short-lived panic-like states in healthy man. This offers the opportunity to assess the anti-panic action of drugs in proof-of-concept studies. However, from current data it is still unclear whether experimental panic in healthy man is a valid translational model. Most such studies in healthy volunteers have been performed using a cholecystokinin tetrapeptide (CCK-4) challenge. While CCK-4 panic was blocked by alprazolam pretreatment, escitalopram showed negative results in healthy man. Preliminary findings on novel investigational drugs and a few problematic results will be reviewed. Small sample sizes in many panic provocation studies, lack of dose-response aspects, and still-insufficient knowledge about the biological underpinning of experimental and spontaneous panic limit the interpretation of existing findings and should inspire further research.
KW - Humans
KW - Drug Design
KW - Alprazolam/administration & dosage
KW - Anti-Anxiety Agents/administration & dosage
KW - Clinical Trials as Topic/trends
KW - Panic Disorder/chemically induced/drug therapy
KW - Tetragastrin/adverse effects
KW - Translational Medical Research/trends
KW - Humans
KW - Drug Design
KW - Alprazolam/administration & dosage
KW - Anti-Anxiety Agents/administration & dosage
KW - Clinical Trials as Topic/trends
KW - Panic Disorder/chemically induced/drug therapy
KW - Tetragastrin/adverse effects
KW - Translational Medical Research/trends
M3 - SCORING: Journal article
VL - 13
SP - 485
EP - 493
JO - DIALOGUES CLIN NEURO
JF - DIALOGUES CLIN NEURO
SN - 1294-8322
IS - 4
M1 - 4
ER -
